临床第四期胃癌转换手术后的术后化疗:倾向性匹配分析
Yasunori Masuike1, Takeshi Omori2, Kazuyoshi Yamamoto2
1Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-Ku, Osaka-Shi, Osaka-Fu, 5418567, Japan. yasunori.masuike@oici.jp.
International journal of clinical oncology
|August 27, 2025
概括
在第四期胃癌手术后的术后化疗,组合疗法与单剂疗法没有整体生存益处. 然而,特定的患者小组可能受益于强化治疗策略.
科学领域:
- 胃肠病学
- 外科瘤学
- 医学瘤学
背景情况:
- 转换手术是临床第四阶段胃癌的一个有前途的策略.
- 术后化疗对生存结果的影响尚不清楚.
- 这项研究比较了手术后单剂和组合化疗方案.
研究的目的:
- 评估术后化疗对第四期胃癌患者的生存结果的影响.
- 为了比较单剂与组合化疗方案的疗效.
- 确定可能受益于特定化疗方法的患者子组.
主要方法:
- 针对第四期胃癌进行胃切除术的128名患者的回顾性研究 (2007-2021年).
- 患者分为单剂和组合术后化疗组.
- 用于生存分析的倾向性得分匹配,卡普兰-梅尔曲线和考克斯模型 (OS和PFS).
主要成果:
- 单剂和组合化疗组的整体存活率 (OS) 或无进展存活率 (PFS) 没有显著差异 (p>0. 05).
- 剩余瘤是低生存率的一个显著预测因素 (p=0. 010).
- 在没有残留瘤的ypStage IV患者中观察到组合治疗的潜在PFS益处 (p=0. 04).
结论:
- 与单剂疗法相比,术后组合化疗没有显著改善整体队列的生存率.
- 特定的小组,特别是没有残留瘤的第4期患者,可能会受益于强化组合治疗.
- 需要进一步的研究来完善第四阶段胃癌的治疗策略.
相关概念视频
Endoscopic Procedures IV: Sigmoidoscopy and Laproscopy
170
Sigmoidoscopy and laparoscopy are distinct medical procedures that enable physicians to internally inspect different parts of the GI tract. Although they serve different purposes, each is essential for diagnosing and, in some cases, treating various medical conditions.
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
170
Peptic Ulcer Disease V: Surgical Management and Nursing Care
406
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
Surgical Interventions for Peptic Ulcer Disease
406
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
321
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
321
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


